These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 3818815)
21. Legal issues in sharing the benefits of biodiversity prospecting. Mays TD; Mazan KD J Ethnopharmacol; 1996 Apr; 51(1-3):93-102; discussion 102-9. PubMed ID: 9213633 [TBL] [Abstract][Full Text] [Related]
22. PDQ: the National Cancer Institute's computerized database for physicians. Fulda PO J La State Med Soc; 1990 Apr; 142(4):49-50. PubMed ID: 2187935 [TBL] [Abstract][Full Text] [Related]
23. The U.S. National Library of Medicine's Toxicology and Environmental Health Information Program. Wexler P Toxicology; 2004 May; 198(1-3):161-8. PubMed ID: 15138039 [TBL] [Abstract][Full Text] [Related]
24. Laboratory oriented computerized drug information system. Young DS; Pestaner LC; Friedman RB Drug Inf J; 1975; 9(2-3):182-9. PubMed ID: 10316628 [No Abstract] [Full Text] [Related]
25. The historical toxicology information/data system--HISTOX. Simon RC; Kovacs GJ Drug Inf J; 1975; 9(2-3):145-53. PubMed ID: 10236968 [No Abstract] [Full Text] [Related]
27. Translational research in cancer complementary and alternative medicine: the National Cancer Institute's Best Case Series Program. Lee CO Clin J Oncol Nurs; 2004 Apr; 8(2):212-4. PubMed ID: 15108425 [TBL] [Abstract][Full Text] [Related]
28. caBIONet--A .NET wrapper to access and process genomic data stored at the National Cancer Institute's Center for Bioinformatics databases. Kraj P; McIndoe RA Bioinformatics; 2005 Aug; 21(16):3456-8. PubMed ID: 15961441 [TBL] [Abstract][Full Text] [Related]
29. The National Cancer Institute's Natural Products Antineoplastic Development Program. Douros J; Suffness M Recent Results Cancer Res; 1980; 70():21-44. PubMed ID: 7355247 [TBL] [Abstract][Full Text] [Related]
30. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Huang R; Wallqvist A; Thanki N; Covell DG Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895 [TBL] [Abstract][Full Text] [Related]
31. Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics. Tolliday N; Clemons PA; Ferraiolo P; Koehler AN; Lewis TA; Li X; Schreiber SL; Gerhard DS; Eliasof S Cancer Res; 2006 Sep; 66(18):8935-42. PubMed ID: 16982730 [TBL] [Abstract][Full Text] [Related]
33. CANCERLINE: a new NLM/NCI data base. Tancredi SA; Amacher RH; Schneider JH J Chem Inf Comput Sci; 1976 Aug; 16(3):128-30. PubMed ID: 1010857 [TBL] [Abstract][Full Text] [Related]
34. The US National Cancer Institute's natural products repository; origins and utility. Brown EC; Newman DJ J Environ Monit; 2006 Aug; 8(8):800-5. PubMed ID: 16896463 [TBL] [Abstract][Full Text] [Related]
35. The National Cancer Institute's cancer information service: a new generation of service and research to the nation. Bright MA J Health Commun; 2005; 10 Suppl 1():7-13. PubMed ID: 16377597 [TBL] [Abstract][Full Text] [Related]
36. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933 [TBL] [Abstract][Full Text] [Related]
37. Improvements in the NIOSH registry of toxic effects of chemical substances. Fang JC; Friedman AE; MacDonald WE; Lewis RJ; Tatken RL Drug Chem Toxicol; 1980; 3(1):35-45. PubMed ID: 6993178 [TBL] [Abstract][Full Text] [Related]
38. Meeting the Challenge: The National Cancer Institute's Central Institutional Review Board for Multi-Site Research. Massett HA; Hampp SL; Goldberg JL; Mooney M; Parreco LK; Minasian L; Montello M; Mishkin GE; Davis C; Abrams JS J Clin Oncol; 2018 Mar; 36(8):819-824. PubMed ID: 29384720 [TBL] [Abstract][Full Text] [Related]
39. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel. Hu K; Yao X Anticancer Drugs; 2001 Jul; 12(6):541-7. PubMed ID: 11460001 [TBL] [Abstract][Full Text] [Related]
40. Historical background of the National Cancer Institute's drug development thrust. Zubrod CG; Schepartz SA; Carter SK Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]